Hypertension and Type 2 Diabetes Mellitus (Phase 4)


A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Blood Pressure Reduction With Ambulatory Blood Pressure Monitoring (ABPM), Safety, and Tolerability of Canagliflozin in the Treatment of Subjects with Hypertension and Type 2 Diabetes Mellitus

Contact Info:

Name: Alma Acosta
Phone: (787) 776-6000


  • 1. Man or woman >21 and <75 years with hypertension and T2DM.
  • 2. Hypertension (SBP of >130 mmHg and <160 mmHg and DBP of >70) on stable doses of 1 to 3 anti-hypertensive agents which must include either one of ACEi or ARB, with or without other anti-hypertensive agents for at least 5 weeks before screening.
  • 3. On stable doses of 1 to 3 oral anti-hyperglycemic agents which must include metformin (2,000 mg-day or maximally tolerated dose), with or without other anti-hyperglycemic agents, such as sulphonylureas (SUs), thiazolidinediones (TZDs), or DPP-4 inhibitors, for at least 8 weeks before screening and has and HbA1C of >7.0% and <10% at screening.


$50.00/site visit + study medication.


Family Clinical Research

Villa Fontana, Carolina 00983, Puerto Rico